Pharmaceuticals
Antennova to Present Latest Data of ATN-037 in a Mini Oral Presentation at ESMO Congress 2024
BOSTON, Sept. 8, 2024 /PRNewswire/ -- Antennova, a clinical-stage biotech company focused on oncology today announced thatit will present the latest data of CD73 small molecule inhibitor ATN-037 in a Mini Oral presentation at the 2024 European Society of Medical Oncology Congress (ESMO Congress 2...
2024-09-09 08:30
1152
ESMO 2024 | Ascentage Pharma to Present Updated Data of Olverembatinib in Patients with SDH-Deficient GIST during a Mini Oral Presentation at the 2024 ESMO Congress
ROCKVILLE, Md. and SUZHOU, China, Sept. 9, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class and best-in-class therapies for malignancies, today announced that it will present the latest c...
2024-09-09 08:25
1799
Sciwind Biosciences Announces Oral Presentations at the European Association for the Study of Diabetes 60th Annual Meeting (EASD 2024)
HANGZHOU, China and SAN FRANCISCO, Sept. 6, 2024 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced that the company will present positive results from a ...
2024-09-06 10:10
2083
Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation
* Medera is a clinical-stage biotechnology company focused on targeting difficult-to-treat cardiovascular diseases using a range of next-generation gene- and cell-based approaches in combination with bioengineered human mini-heart drug discovery and screening technology platforms * Transactio...
2024-09-05 20:00
2570
Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration
NANJING, China, Sept. 5, 2024 /PRNewswire/ -- On September 2, 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual tablets), an innovative drug for stroke, has been granted the Breakthrough Therapy designation by the U....
2024-09-05 13:49
1271
Chugai Pharma Taiwan wins Social Empowerment and Green Leadership Categories at the Asia Responsible Enterprise Awards 2024
SINGAPORE, Sept. 4, 2024 /PRNewswire/ -- The Asia Responsible Enterprise Awards (AREA) 2024 honored Chugai Pharma Taiwan as an outstanding business leader that champions sustainable and responsible business practices. Presented by leading regional NGO Enterprise Asia, the AREA ceremony was held i...
2024-09-05 10:47
1563
Veeva Vault CRM Suite to Unlock Greater Customer Centricity with Launch of Service Center
Expanded suite to unify sales, marketing, medical and service through a
connected software and data foundation
SINGAPORE, Sept. 5, 2024 /PRNewswire/ -- Veeva Systems
2024-09-05 09:00
1815
Grand launch | Sanyou Bio monkeypox antibody made a great breakthrough
SHANGHAI, Sept. 4, 2024 /PRNewswire/ -- On August 28, 2024, Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. announced the launch of 65 kinds of monkeypox antibodies, antigens and cell lines, which has won wide praise from the public. Monkeypox human antibody, as the core product launched by Sanyo...
2024-09-05 08:00
1117
TraceLink's Magnum Release of its Opus Platform Will Revolutionize Supply Chain Management by Enabling All Businesses to Digitalize their End-to-End Supply Networks
With real-time information from all supply chain partners, Supply Chain Managers can reduce inventory and stock-out while improving service levels and lead times BOSTON, Sept. 4, 2024 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the ...
2024-09-04 22:00
1665
LakeShore Biopharma Announces Leadership Transitions
GAITHERSBURG, Md., Sept. 4, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for ...
2024-09-04 20:00
1254
LakeShore Biopharma Announces Leadership Transitions
GAITHERSBURG, Md., Sept. 4, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for ...
2024-09-04 20:00
1476
HKBU develops Chinese medicine for ulcerative colitis approved by National Medical Products Administration for clinical trial
HONG KONG, Sept. 4, 2024 /PRNewswire/ -- The Centre for Chinese Herbal Medicine Drug Development (CDD) at Hong KongBaptist University (HKBU) has achieved a significant milestone in developing a novel Chinese herbal formulation for ulcerative colitis remission maintenance. Following a submission o...
2024-09-04 15:13
1491
Innovent Receives Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α Bispecific Antibody Fusion Protein) as Monotherapy for Advanced Melanoma
SAN FRANCISCO and SUZHOU, China, Sept. 4, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune...
2024-09-04 08:00
4244
IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances
MELBOURNE, Australia, Sept. 4, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Company's IPAX-1 Phase I study has been published inNeuro-Oncology Advances, confirming the safety and tolerability profile, and early efficacy of TLX101 thera...
2024-09-04 06:57
1907
Biostar Announces Completion of Patient Recruitment for US Phase 1 Clinical Study of Utidelone Capsule
SAN FRANCISCO, Sept. 3, 2024 /PRNewswire/ -- Biostar Pharma, Inc., the US subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic biology driven biopharma company focusing on the discovery, development and commercialization of innovative oncology drugs, is pleased to announce...
2024-09-03 20:00
1286
Skyline Therapeutics' Novel Gene Therapy SKG1108 Receives FDA Orphan Drug Designation for Retinitis Pigmentosa
BOSTON and SHANGHAI, Sept. 3, 2024 /PRNewswire/ -- Skyline Therapeutics, an innovation-driven gene therapy company committed to developing unique and novel solutions for rare and severe diseases, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) fo...
2024-09-03 18:00
1131
GC Biopharma and Hanmi Pharmaceutical Receives IND Clearance for Phase 1/2 Clinical Trial from the U.S. FDA
* Co-development of innovative new drug for the treatment of Fabry disease as "the world's first once-monthly subcutaneous treatment" * Improves efficacy compared to existing treatment for kidney function, vascular disease, and peripheral nerve disorders YONGIN, South Korea, Sept. 3, 2024 /PR...
2024-09-03 15:59
1254
Caliway Announces the Initiation of Subject Recruitment in CBL-514 Phase 2b Study for Dercum's Disease
NEW TAIPEI CITY, Sept. 3, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) announced that the subject recruitment of CBL-514 Phase2b study for Dercum's disease (CBL-0202 DD Phase2b study, NCT06303570) has been initiated. The study results are anticipated in Q4 2025. CBL-0202DD study i...
2024-09-03 15:18
1241
Seegene and Springer Nature Launch 'Nature Awards MDx Impact Grants' to Innovate Syndromic PCR Diagnostic Assays
- Nature Awards MDx Impact Grants in partnership with Seegene extends commitment to external innovation. - Global research teams invited to submit proposals to develop new tests for human infectious diseases. Application deadline:December 2, 2024. - Nature Awards to lead the application and eva...
2024-09-02 21:00
2259
Simcere Zaiming collaborates with TargetRx to introduce a third-generation ALK inhibitor
NANJING, China, Sept. 2, 2024 /PRNewswire/ -- On September 02, 2024, Simcere Zaiming, an innovative oncology company under Simcere Pharmaceutical Group (2096.HK), announced a collaboration agreement with Shenzhen TargetRx Inc. The partnership focuses on the ALK/ROS1 dual receptor tyrosine kinase ...
2024-09-02 20:24
1666
Week's Top Stories
Most Reposted
LONG AN INTERNATIONAL PORT JOINS 12TH PORTECH ASIA SUMMIT 2025 IN MALAYSIA
[Picked up by 337 media titles]
2025-01-18 03:30
Supported by the Luxembourg Government, The Luxembourg House of Financial Technology (LHoFT) and the Asian Development Bank (ADB) Announce the 2nd Edition of Catapult | SE Asia 2025
[Picked up by 313 media titles]
2025-01-22 15:38
Hong Kong Airlines Takes Off to Australia's Gold Coast Bringing Popular Travel Option for the Chinese New Year
[Picked up by 311 media titles]
2025-01-18 17:00
dss⁺ Announces Strategic Changes to Executive Leadership Team in Asia Pacific Accelerating growth and impact for high-hazard industries in the region
[Picked up by 309 media titles]
2025-01-21 16:00
HARD ROCK HOTEL BALI ACHIEVES PRESTIGIOUS GSTC CERTIFICATION
[Picked up by 306 media titles]
2025-01-20 14:27
Most Read
LONG AN INTERNATIONAL PORT JOINS 12TH PORTECH ASIA SUMMIT 2025 IN MALAYSIA
2025-01-18 03:30
12431
Hong Kong Airlines Takes Off to Australia's Gold Coast Bringing Popular Travel Option for the Chinese New Year
2025-01-18 17:00
11631
EZGO ANNOUNCES FINANCIAL RESULTS FOR FISCAL YEAR 2024
2025-01-18 06:45
8827
MONTECH Debuts the Heritage: A New Era of Leather Craft & High-End PC
2025-01-18 22:00
5503
